Does the media refer more to MRNA or INO?

In the previous week, Moderna had 30 more articles in the media than Inovio Pharmaceuticals. MarketBeat recorded 37 mentions for Moderna and 7 mentions for Inovio Pharmaceuticals. Inovio Pharmaceuticals' average media sentiment score of 0.67 beat Moderna's score of 0.45 indicating that Inovio Pharmaceuticals is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Moderna 12 Very Positive mention(s) 6 Positive mention(s) 9 Neutral mention(s) 6 Negative mention(s) 1 Very Negative mention(s) Neutral Inovio Pharmaceuticals 2 Very Positive mention(s) 0 Positive mention(s) 5 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media favor ELMD or INO?

In the previous week, Inovio Pharmaceuticals had 5 more articles in the media than Electromed. MarketBeat recorded 7 mentions for Inovio Pharmaceuticals and 2 mentions for Electromed. Electromed's average media sentiment score of 1.66 beat Inovio Pharmaceuticals' score of 0.67 indicating that Electromed is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Electromed 2 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive Inovio Pharmaceuticals 2 Very Positive mention(s) 0 Positive mention(s) 5 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media refer more to CV or INO?

In the previous week, Inovio Pharmaceuticals had 3 more articles in the media than CapsoVision. MarketBeat recorded 7 mentions for Inovio Pharmaceuticals and 4 mentions for CapsoVision. CapsoVision's average media sentiment score of 1.53 beat Inovio Pharmaceuticals' score of 0.67 indicating that CapsoVision is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment CapsoVision 2 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive Inovio Pharmaceuticals 2 Very Positive mention(s) 0 Positive mention(s) 5 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media prefer CARL or INO?

In the previous week, Inovio Pharmaceuticals had 4 more articles in the media than Carlsmed. MarketBeat recorded 7 mentions for Inovio Pharmaceuticals and 3 mentions for Carlsmed. Inovio Pharmaceuticals' average media sentiment score of 0.67 beat Carlsmed's score of 0.56 indicating that Inovio Pharmaceuticals is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Carlsmed 1 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Inovio Pharmaceuticals 2 Very Positive mention(s) 0 Positive mention(s) 5 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media favor SGHT or INO?

In the previous week, Sight Sciences had 1 more articles in the media than Inovio Pharmaceuticals. MarketBeat recorded 8 mentions for Sight Sciences and 7 mentions for Inovio Pharmaceuticals. Inovio Pharmaceuticals' average media sentiment score of 0.67 beat Sight Sciences' score of 0.59 indicating that Inovio Pharmaceuticals is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Sight Sciences 2 Very Positive mention(s) 0 Positive mention(s) 5 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Inovio Pharmaceuticals 2 Very Positive mention(s) 0 Positive mention(s) 5 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Inovio Pharmaceuticals (INO) Competitors

$0.68 +0.02 (+3.20%)

Closing price 07/31/2026 04:00 PM Eastern

Extended Trading

$0.67 -0.01 (-0.74%)

As of 07/31/2026 07:59 PM Eastern

Compare

INO vs. MRNA, ELMD, CV, CARL, and SGHT

Should you buy Inovio Pharmaceuticals stock or one of its competitors? MarketBeat compares Inovio Pharmaceuticals with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Inovio Pharmaceuticals include Moderna (MRNA), Electromed (ELMD), CapsoVision (CV), Carlsmed (CARL), and Sight Sciences (SGHT).

How does Inovio Pharmaceuticals compare to Moderna?

Moderna (NASDAQ:MRNA) and Inovio Pharmaceuticals (NASDAQ:INO) are both healthcare companies, but which is the better stock? We will contrast the two businesses based on the strength of their media sentiment, valuation, dividends, institutional ownership, profitability, analyst recommendations, earnings and risk.

Inovio Pharmaceuticals has lower revenue, but higher earnings than Moderna. Moderna is trading at a lower price-to-earnings ratio than Inovio Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Moderna	$1.94B	11.19	-$2.82B	-$8.15	N/A
Inovio Pharmaceuticals	$60K	928.28	-$84.95M	-$1.45	N/A

Moderna has a beta of 0.94, meaning that its stock price is 6% less volatile than the broader market. Comparatively, Inovio Pharmaceuticals has a beta of 1.48, meaning that its stock price is 48% more volatile than the broader market.

Moderna currently has a consensus price target of $40.00, suggesting a potential downside of 27.03%. Inovio Pharmaceuticals has a consensus price target of $4.25, suggesting a potential upside of 527.77%. Given Inovio Pharmaceuticals' stronger consensus rating and higher probable upside, analysts plainly believe Inovio Pharmaceuticals is more favorable than Moderna.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Moderna	5 Sell rating(s)	10 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	1.82
Inovio Pharmaceuticals	1 Sell rating(s)	2 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.43

75.3% of Moderna shares are held by institutional investors. Comparatively, 26.8% of Inovio Pharmaceuticals shares are held by institutional investors. 10.8% of Moderna shares are held by company insiders. Comparatively, 1.7% of Inovio Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Inovio Pharmaceuticals has a net margin of 0.00% compared to Moderna's net margin of -143.55%. Moderna's return on equity of -26.64% beat Inovio Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Moderna	-143.55%	-26.64%	-19.32%
Inovio Pharmaceuticals	N/A	-489.79%	-95.40%

In the previous week, Moderna had 30 more articles in the media than Inovio Pharmaceuticals. MarketBeat recorded 37 mentions for Moderna and 7 mentions for Inovio Pharmaceuticals. Inovio Pharmaceuticals' average media sentiment score of 0.67 beat Moderna's score of 0.45 indicating that Inovio Pharmaceuticals is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Moderna	12 Very Positive mention(s)	6 Positive mention(s)	9 Neutral mention(s)	6 Negative mention(s)	1 Very Negative mention(s)	Neutral
Inovio Pharmaceuticals	2 Very Positive mention(s)	0 Positive mention(s)	5 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Inovio Pharmaceuticals beats Moderna on 10 of the 16 factors compared between the two stocks.

How does Inovio Pharmaceuticals compare to Electromed?

Electromed (NYSE:ELMD) and Inovio Pharmaceuticals (NASDAQ:INO) are both small-cap healthcare companies, but which is the superior stock? We will compare the two companies based on the strength of their earnings, valuation, media sentiment, analyst recommendations, risk, dividends, institutional ownership and profitability.

Electromed has a beta of 0.5, indicating that its share price is 50% less volatile than the broader market. Comparatively, Inovio Pharmaceuticals has a beta of 1.48, indicating that its share price is 48% more volatile than the broader market.

Electromed has higher revenue and earnings than Inovio Pharmaceuticals. Inovio Pharmaceuticals is trading at a lower price-to-earnings ratio than Electromed, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Electromed	$71.75M	4.70	$5.15M	$1.17	34.81
Inovio Pharmaceuticals	$60K	928.28	-$84.95M	-$1.45	N/A

Electromed has a net margin of 11.34% compared to Inovio Pharmaceuticals' net margin of 0.00%. Electromed's return on equity of 15.71% beat Inovio Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Electromed	11.34%	15.71%	13.37%
Inovio Pharmaceuticals	N/A	-489.79%	-95.40%

In the previous week, Inovio Pharmaceuticals had 5 more articles in the media than Electromed. MarketBeat recorded 7 mentions for Inovio Pharmaceuticals and 2 mentions for Electromed. Electromed's average media sentiment score of 1.66 beat Inovio Pharmaceuticals' score of 0.67 indicating that Electromed is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Electromed	2 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive
Inovio Pharmaceuticals	2 Very Positive mention(s)	0 Positive mention(s)	5 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

40.8% of Electromed shares are held by institutional investors. Comparatively, 26.8% of Inovio Pharmaceuticals shares are held by institutional investors. 10.5% of Electromed shares are held by insiders. Comparatively, 1.7% of Inovio Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Electromed currently has a consensus target price of $37.50, suggesting a potential downside of 7.93%. Inovio Pharmaceuticals has a consensus target price of $4.25, suggesting a potential upside of 527.77%. Given Inovio Pharmaceuticals' higher probable upside, analysts plainly believe Inovio Pharmaceuticals is more favorable than Electromed.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Electromed	0 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.75
Inovio Pharmaceuticals	1 Sell rating(s)	2 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.43

Summary

Electromed beats Inovio Pharmaceuticals on 11 of the 16 factors compared between the two stocks.

How does Inovio Pharmaceuticals compare to CapsoVision?

CapsoVision (NASDAQ:CV) and Inovio Pharmaceuticals (NASDAQ:INO) are both small-cap healthcare companies, but which is the better business? We will compare the two businesses based on the strength of their dividends, earnings, risk, analyst recommendations, valuation, institutional ownership, profitability and media sentiment.

26.8% of Inovio Pharmaceuticals shares are held by institutional investors. 2.3% of CapsoVision shares are held by company insiders. Comparatively, 1.7% of Inovio Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

CapsoVision has higher revenue and earnings than Inovio Pharmaceuticals. CapsoVision is trading at a lower price-to-earnings ratio than Inovio Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
CapsoVision	$13.55M	24.26	-$25.32M	-$2.34	N/A
Inovio Pharmaceuticals	$60K	928.28	-$84.95M	-$1.45	N/A

Inovio Pharmaceuticals has a net margin of 0.00% compared to CapsoVision's net margin of -198.87%. CapsoVision's return on equity of 0.00% beat Inovio Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
CapsoVision	-198.87%	N/A	-136.03%
Inovio Pharmaceuticals	N/A	-489.79%	-95.40%

CapsoVision presently has a consensus price target of $8.50, suggesting a potential upside of 29.18%. Inovio Pharmaceuticals has a consensus price target of $4.25, suggesting a potential upside of 527.77%. Given Inovio Pharmaceuticals' higher possible upside, analysts clearly believe Inovio Pharmaceuticals is more favorable than CapsoVision.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
CapsoVision	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	1 Strong Buy rating(s)	2.50
Inovio Pharmaceuticals	1 Sell rating(s)	2 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.43

In the previous week, Inovio Pharmaceuticals had 3 more articles in the media than CapsoVision. MarketBeat recorded 7 mentions for Inovio Pharmaceuticals and 4 mentions for CapsoVision. CapsoVision's average media sentiment score of 1.53 beat Inovio Pharmaceuticals' score of 0.67 indicating that CapsoVision is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
CapsoVision	2 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive
Inovio Pharmaceuticals	2 Very Positive mention(s)	0 Positive mention(s)	5 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Inovio Pharmaceuticals beats CapsoVision on 9 of the 16 factors compared between the two stocks.

How does Inovio Pharmaceuticals compare to Carlsmed?

Carlsmed (NASDAQ:CARL) and Inovio Pharmaceuticals (NASDAQ:INO) are both small-cap healthcare companies, but which is the superior investment? We will compare the two companies based on the strength of their earnings, analyst recommendations, valuation, profitability, dividends, risk, media sentiment and institutional ownership.

Inovio Pharmaceuticals has a net margin of 0.00% compared to Carlsmed's net margin of -57.76%. Carlsmed's return on equity of -60.74% beat Inovio Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Carlsmed	-57.76%	-60.74%	-29.84%
Inovio Pharmaceuticals	N/A	-489.79%	-95.40%

Carlsmed presently has a consensus price target of $18.75, indicating a potential upside of 48.93%. Inovio Pharmaceuticals has a consensus price target of $4.25, indicating a potential upside of 527.77%. Given Inovio Pharmaceuticals' higher possible upside, analysts clearly believe Inovio Pharmaceuticals is more favorable than Carlsmed.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Carlsmed	1 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.50
Inovio Pharmaceuticals	1 Sell rating(s)	2 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.43

In the previous week, Inovio Pharmaceuticals had 4 more articles in the media than Carlsmed. MarketBeat recorded 7 mentions for Inovio Pharmaceuticals and 3 mentions for Carlsmed. Inovio Pharmaceuticals' average media sentiment score of 0.67 beat Carlsmed's score of 0.56 indicating that Inovio Pharmaceuticals is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Carlsmed	1 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Inovio Pharmaceuticals	2 Very Positive mention(s)	0 Positive mention(s)	5 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

26.8% of Inovio Pharmaceuticals shares are held by institutional investors. 12.9% of Carlsmed shares are held by insiders. Comparatively, 1.7% of Inovio Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Carlsmed has higher revenue and earnings than Inovio Pharmaceuticals. Carlsmed is trading at a lower price-to-earnings ratio than Inovio Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Carlsmed	$56.44M	6.06	-$29.63M	-$2.51	N/A
Inovio Pharmaceuticals	$60K	928.28	-$84.95M	-$1.45	N/A

Summary

Inovio Pharmaceuticals beats Carlsmed on 8 of the 14 factors compared between the two stocks.

How does Inovio Pharmaceuticals compare to Sight Sciences?

Sight Sciences (NASDAQ:SGHT) and Inovio Pharmaceuticals (NASDAQ:INO) are both small-cap healthcare companies, but which is the better investment? We will contrast the two businesses based on the strength of their dividends, profitability, media sentiment, earnings, institutional ownership, risk, analyst recommendations and valuation.

55.5% of Sight Sciences shares are held by institutional investors. Comparatively, 26.8% of Inovio Pharmaceuticals shares are held by institutional investors. 30.4% of Sight Sciences shares are held by insiders. Comparatively, 1.7% of Inovio Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Sight Sciences has higher revenue and earnings than Inovio Pharmaceuticals. Sight Sciences is trading at a lower price-to-earnings ratio than Inovio Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Sight Sciences	$77.36M	3.70	-$38.43M	-$0.71	N/A
Inovio Pharmaceuticals	$60K	928.28	-$84.95M	-$1.45	N/A

Sight Sciences has a beta of 2.38, meaning that its stock price is 138% more volatile than the broader market. Comparatively, Inovio Pharmaceuticals has a beta of 1.48, meaning that its stock price is 48% more volatile than the broader market.

Sight Sciences currently has a consensus target price of $7.75, suggesting a potential upside of 47.34%. Inovio Pharmaceuticals has a consensus target price of $4.25, suggesting a potential upside of 527.77%. Given Inovio Pharmaceuticals' higher possible upside, analysts clearly believe Inovio Pharmaceuticals is more favorable than Sight Sciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Sight Sciences	1 Sell rating(s)	3 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.44
Inovio Pharmaceuticals	1 Sell rating(s)	2 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.43

Inovio Pharmaceuticals has a net margin of 0.00% compared to Sight Sciences' net margin of -46.83%. Sight Sciences' return on equity of -52.34% beat Inovio Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Sight Sciences	-46.83%	-52.34%	-28.49%
Inovio Pharmaceuticals	N/A	-489.79%	-95.40%

In the previous week, Sight Sciences had 1 more articles in the media than Inovio Pharmaceuticals. MarketBeat recorded 8 mentions for Sight Sciences and 7 mentions for Inovio Pharmaceuticals. Inovio Pharmaceuticals' average media sentiment score of 0.67 beat Sight Sciences' score of 0.59 indicating that Inovio Pharmaceuticals is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Sight Sciences	2 Very Positive mention(s)	0 Positive mention(s)	5 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Inovio Pharmaceuticals	2 Very Positive mention(s)	0 Positive mention(s)	5 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Sight Sciences beats Inovio Pharmaceuticals on 11 of the 16 factors compared between the two stocks.

Get Inovio Pharmaceuticals News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding INO and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

INO vs. The Competition

Export

Metric	Inovio Pharmaceuticals	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$53.97M	$3.61B	$7.22B	$12.30B
Dividend Yield	N/A	3.78%	2.59%	9.45%
P/E Ratio	-0.47	7.71	280.89	24.67
Price / Sales	928.28	1,260.84	586.86	89.25
Price / Cash	N/A	93.43	71.02	59.62
Price / Book	1.88	16.81	11.07	5.90
Net Income	-$84.95M	-$12.44M	$3.49B	$336.16M
7 Day Performance	-30.21%	-1.42%	-0.24%	0.10%
1 Month Performance	-43.11%	-7.52%	-2.98%	-5.65%
1 Year Performance	-52.66%	48.83%	61.99%	18.86%

Inovio Pharmaceuticals Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
INO Inovio Pharmaceuticals	2.1467 of 5 stars	$0.68 +3.2%	$4.25 +527.8%	-52.3%	$53.97M	$60K	N/A	320	News Coverage Analyst Upgrade High Trading Volume
MRNA Moderna	1.4608 of 5 stars	$61.31 -0.8%	$38.27 -37.6%	+85.5%	$24.31B	$1.94B	N/A	4,700	Trending News Earnings Report Options Volume
ELMD Electromed	1.4784 of 5 stars	$42.42 +0.7%	$37.50 -11.6%	+123.7%	$351.20M	$71.75M	56.55	160
CV CapsoVision	2.824 of 5 stars	$6.59 -1.9%	$8.50 +29.1%	+70.0%	$329.19M	$13.55M	N/A	90	Insider Trade
CARL Carlsmed	2.068 of 5 stars	$11.55 -1.0%	$18.75 +62.4%	N/A	$315.97M	$50.51M	N/A	100	News Coverage

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:INO) was last updated on 8/1/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Inovio Pharmaceuticals (INO) Competitors

INO vs. MRNA, ELMD, CV, CARL, and SGHT

How does Inovio Pharmaceuticals compare to Moderna?

Summary

How does Inovio Pharmaceuticals compare to Electromed?

Summary

How does Inovio Pharmaceuticals compare to CapsoVision?

Summary

How does Inovio Pharmaceuticals compare to Carlsmed?

Summary

How does Inovio Pharmaceuticals compare to Sight Sciences?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

INO vs. The Competition

Inovio Pharmaceuticals Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Inovio Pharmaceuticals (INO) Competitors

INO vs. MRNA, ELMD, CV, CARL, and SGHT

How does Inovio Pharmaceuticals compare to Moderna?

Which has preferable valuation & earnings, MRNA or INO?

Which has more risk and volatility, MRNA or INO?

Do analysts rate MRNA or INO?

Do institutionals & insiders hold more shares of MRNA or INO?

Is MRNA or INO more profitable?

Does the media refer more to MRNA or INO?

Summary

How does Inovio Pharmaceuticals compare to Electromed?

Which has more risk and volatility, ELMD or INO?

Which has stronger earnings & valuation, ELMD or INO?

Is ELMD or INO more profitable?

Does the media favor ELMD or INO?

Do institutionals and insiders hold more shares of ELMD or INO?

Do analysts prefer ELMD or INO?

Summary

How does Inovio Pharmaceuticals compare to CapsoVision?

Do insiders and institutionals hold more shares of CV or INO?

Which has better valuation & earnings, CV or INO?

Is CV or INO more profitable?

Do analysts prefer CV or INO?

Does the media refer more to CV or INO?

Summary

How does Inovio Pharmaceuticals compare to Carlsmed?

Is CARL or INO more profitable?

Do analysts prefer CARL or INO?

Does the media prefer CARL or INO?

Do insiders & institutionals have more ownership in CARL or INO?

Which has stronger earnings and valuation, CARL or INO?

Summary

How does Inovio Pharmaceuticals compare to Sight Sciences?

Do institutionals & insiders hold more shares of SGHT or INO?

Which has higher valuation & earnings, SGHT or INO?

Which has more volatility and risk, SGHT or INO?

Do analysts prefer SGHT or INO?

Is SGHT or INO more profitable?

Does the media favor SGHT or INO?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

INO vs. The Competition

Inovio Pharmaceuticals Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools